A pooled analysis of the phase 3 CIMPASI-1 and CIMPASI-2 studies with focus on psoriasis of head and neck showed that certolizumab pegol, an anti-TNFα monoclonal antibody, in a dose of 400 mg every second week leads to greatest improvement of this difficult-to-treat area .
The new assessment included data from 461 adult patients with moderate-to-severe psoriasis from the CIMPASI-1 and CIMPASI-2 trials. The analysis focussed on the head and neck was chosen, as visible psoriasis in these areas has a disproportionately high impact on patients’ quality of life .
Inclusion criteria also included a Psoriasis Area and Severity Index score (PASI) of ≥ 12, body surface area (BSA) ≥ 10%, and Physician's Global Assessment (PGA) of ≥ 3 at baseline. Randomisation allocated 186 patients to the group treated with 200 mg certolizumab pegol every second week, 175 patients receiving 400 mg certolizumab every second week, and 100 patients to placebo. The initial...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« New guidance on rosacea therapy according to phenotype Next Article
Selective IL-23 blocker crushes fumaric acids in all assessed efficacy endpoints »
Table of Contents: EADV 2019
Spotlight on Psoriasis
New Insights in Photoprotection
Rosacea – from new spectrum to new therapy
Best of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.